Wide spread of OXA-23-producing carbapenem-resistant Acinetobacter baumannii belonging to clonal complex II in different hospitals in Lebanon

Atrouni, Ahmad Al; Hamzé, Monzer; Jisr, Tamima; Lemarié, Carole; Eveillard, Matthieu; Joly-Guillou, Marie-Laure; Kempf, Marie

doi:10.1016/j.ijid.2016.09.017

Cited by 62 publications

(66 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these OXA families, OXA-23-like was found to be the most prevalent enzyme associated with CRAB infections in Lebanon. OXA-24-like and OXA-58-like have also been reported in this country, but at lower rates (Zarrilli et al, 2008; Al Atrouni et al, 2016). Similar to what is being reported all around the world, CRAB rates are being increasingly reported in Lebanon (Chamoun et al, 2016; Schultz et al, 2016).…”

Section: Introductionmentioning

confidence: 72%

“…However, the main cause of carbapenem resistance is the acquisition of other types of oxacillinases (Howard et al, 2012). OXA-23-like, OXA-24-like, OXA-58-like, as well as the recently discovered OXA-143-like and OXA-235-like, are globally associated with the emergence of CRAB (Al Atrouni et al, 2016). Among these OXA families, OXA-23-like was found to be the most prevalent enzyme associated with CRAB infections in Lebanon.…”

Section: Introductionmentioning

confidence: 98%

“…Similar to what is being reported all around the world, CRAB rates are being increasingly reported in Lebanon (Chamoun et al, 2016; Schultz et al, 2016). One Lebanese study showed an increase in the incidence of CRAB isolates from 50.8% in 2011 to 76.5% in 2015 (Al Atrouni et al, 2016; Chamoun et al, 2016). Moreover, International Clone II (ICII) was shown to be the most disseminated clone in this country (Al Atrouni et al, 2016; Schultz et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

“…One Lebanese study showed an increase in the incidence of CRAB isolates from 50.8% in 2011 to 76.5% in 2015 (Al Atrouni et al, 2016; Chamoun et al, 2016). Moreover, International Clone II (ICII) was shown to be the most disseminated clone in this country (Al Atrouni et al, 2016; Schultz et al, 2016). …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

In vitro Evaluation of the Colistin-Carbapenem Combination in Clinical Isolates of A. baumannii Using the Checkerboard, Etest, and Time-Kill Curve Techniques

Soudeiha

Dahdouh

Azar

et al. 2017

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

The worldwide increase in the emergence of carbapenem resistant Acinetobacter baumannii (CRAB) calls for the investigation into alternative approaches for treatment. This study aims to evaluate colistin-carbapenem combinations against Acinetobacter spp., in order to potentially reduce the need for high concentrations of antibiotics in therapy. This study was conducted on 100 non-duplicate Acinetobacter isolates that were collected from different patients admitted at Saint George Hospital-University Medical Center in Beirut. The isolates were identified using API 20NE strips, which contain the necessary agents to cover a panel of biochemical tests, and confirmed by PCR amplification of blaOXA−51−like. Activities of colistin, meropenem and imipenem against Acinetobacter isolates were determined by ETEST and microdilution methods, and interpreted according to the guidelines of the Clinical and Laboratory Standards Institute. In addition, PCR amplifications of the most common beta lactamases contributing to carbapenem resistance were performed. Tri locus PCR–typing was also performed to determine the international clonality of the isolates. Checkerboard, ETEST and time kill curves were then performed to determine the effect of the colistin-carbapenem combinations. The synergistic potential of the combination was then determined by calculating the Fractional Inhibitory Concentration Index (FICI), which is an index that indicates additivity, synergism, or antagonism between the antimicrobial agents. In this study, 84% of the isolates were resistant to meropenem, 78% to imipenem, and only one strain was resistant to colistin. 79% of the isolates harbored blaOXA−23−like and pertained to the International Clone II. An additive effect for the colistin-carbapenem combination was observed using all three methods. The combination of colistin-meropenem showed better effects as compared to colistin-imipenem (p < 0.05). The colistin-meropenem and colistin-imipenem combinations also showed a decrease of 2.6 and 2.8-fold, respectively in the MIC of colistin (p < 0.001). Time kill assays additionally showed synergistic effects for a few isolates, and no bacterial re-growth was detected following a 24 h incubation. Our study showed that the combination of colistin with carbapenems could be a promising antimicrobial strategy in treating CRAB infections and potentially lowering colistin toxicity related to higher doses used in colistin monotherapy.

show abstract

Section: Introductionmentioning

confidence: 72%

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

In vitro Evaluation of the Colistin-Carbapenem Combination in Clinical Isolates of A. baumannii Using the Checkerboard, Etest, and Time-Kill Curve Techniques

Soudeiha

Dahdouh

Azar

et al. 2017

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…The bla OXA-23 gene has been disseminated worldwide, and the frequency of OXA-23-producing A. baumannii strains is significantly high (Mugnier et al, 2010; Al-Agamy et al, 2016). One recent report from Lebanon showed 76.5% of 119 A. baumannii isolates are resistant to carbapenems, and OXA-23 β-lactamases have been found in 82 isolates (Al Atrouni et al, 2016). Insertion of IS Aba1 in the bla OXA-23 promoter sequence has been reported to be associated with overexpression of bla OXA-23 , bla OXA-51 , or bla OXA-58 in A. baumannii (Turton et al, 2006a).…”

Section: Antimicrobial Resistance Of a Baumanniimentioning

confidence: 99%

Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options

Lee

Park

et al. 2017

Front. Cell. Infect. Microbiol.

714

585

View full text Add to dashboard Cite

Acinetobacter baumannii is undoubtedly one of the most successful pathogens responsible for hospital-acquired nosocomial infections in the modern healthcare system. Due to the prevalence of infections and outbreaks caused by multi-drug resistant A. baumannii, few antibiotics are effective for treating infections caused by this pathogen. To overcome this problem, knowledge of the pathogenesis and antibiotic resistance mechanisms of A. baumannii is important. In this review, we summarize current studies on the virulence factors that contribute to A. baumannii pathogenesis, including porins, capsular polysaccharides, lipopolysaccharides, phospholipases, outer membrane vesicles, metal acquisition systems, and protein secretion systems. Mechanisms of antibiotic resistance of this organism, including acquirement of β-lactamases, up-regulation of multidrug efflux pumps, modification of aminoglycosides, permeability defects, and alteration of target sites, are also discussed. Lastly, novel prospective treatment options for infections caused by multi-drug resistant A. baumannii are summarized.

show abstract

Genetic basis of antimicrobial resistance, virulence features and phylogenomics of carbapenem-resistant Acinetobacter baumannii clinical isolates

Lukovic,

Kabic,

Dragicevic

et al. 2024

Infection

View full text Add to dashboard Cite

Wide spread of OXA-23-producing carbapenem-resistant Acinetobacter baumannii belonging to clonal complex II in different hospitals in Lebanon

Cited by 62 publications

References 40 publications

In vitro Evaluation of the Colistin-Carbapenem Combination in Clinical Isolates of A. baumannii Using the Checkerboard, Etest, and Time-Kill Curve Techniques

In vitro Evaluation of the Colistin-Carbapenem Combination in Clinical Isolates of A. baumannii Using the Checkerboard, Etest, and Time-Kill Curve Techniques

Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options

Genetic basis of antimicrobial resistance, virulence features and phylogenomics of carbapenem-resistant Acinetobacter baumannii clinical isolates

Contact Info

Product

Resources

About